凯杰2025年第一季度财报出炉！业绩超预期，销售额同比增长5%

Core Viewpoint - QIAGEN reported a strong start to Q1 2025 with net sales of $483 million, a 5% increase year-over-year, driven by efficiency improvements and the discontinuation of the NeuMoDx clinical PCR testing system [2][3][5]. Financial Performance - Net sales for Q1 2025 reached $483 million, up from $459 million in Q1 2024, reflecting a 5% increase. On a constant exchange rate (CER) basis, net sales grew by 7% [6]. - Adjusted operating income rose by 22% to $144 million, with an adjusted operating margin increasing by 4.1 percentage points to 29.8% [7]. - Adjusted diluted EPS for Q1 2025 was $0.55, exceeding the expected minimum of $0.50, while diluted EPS was $0.41, up from $0.36 in Q1 2024 [8]. Sales Breakdown - Diagnostic solutions sales grew by 11% year-over-year, with a 14% increase when excluding the discontinued NeuMoDx system. Key contributors included QuantiFERON and QIAstat-Dx, which saw sales growth of 16% and 37% respectively [9][10]. - PCR/nucleic acid amplification sales increased by 14%, primarily due to the adoption of the QIAcuity digital PCR system [10]. - Sample technologies experienced a slight decline of 1%, attributed to reduced demand for manual kits and cautious capital spending trends [9]. Future Outlook - QIAGEN reaffirmed its 2025 fiscal year net sales growth expectation of approximately 4%, with core sales growth projected at around 5% [5][13]. - The adjusted diluted EPS forecast for 2025 was raised to approximately $2.35, with an operating margin target of over 30% [5][13].